来凯医药：LAE102针对治疗肥胖症的I期多剂量扩展研究完成首例受试者给药

Group 1 - The core point of the article is that Laekna Therapeutics has initiated a Phase I multi-dose expansion study for LAE102, aimed at treating obesity in China, and has completed the dosing of the first subject [1] Group 2 - The study is part of the company's efforts to advance its pipeline in the obesity treatment sector [1] - The announcement was made on December 22, indicating the company's ongoing commitment to research and development in the pharmaceutical industry [1] - The initiation of this study may present potential investment opportunities in the healthcare sector, particularly in obesity treatments [1]